Skip to main
STOK

STOK Stock Forecast & Price Target

STOK Analyst Ratings

Based on 9 analyst ratings
Strong Buy
Strong Buy 67%
Buy 22%
Hold 11%
Sell 0%
Strong Sell 0%

Bulls say

Stoke Therapeutics has demonstrated a positive financial trajectory, with FY25 revenue rising significantly to $184 million from $36.6 million in FY24, primarily due to a substantial $165 million upfront payment from its collaboration with Biogen. The ongoing Phase III EMPEROR study of zorevunersen in Dravet syndrome shows promising early readouts, with various statistically significant improvements in seizure reduction, which supports a favorable outlook for further clinical progress. Additionally, the company's R&D expenditure increased to $138 million, reflecting its commitment to expanding its portfolio of antisense oligonucleotides and investing in innovative treatments, indicating a strong pipeline and potential for future growth.

Bears say

Stoke Therapeutics Inc faces significant risks that contribute to a negative outlook on its stock, primarily due to reliance on key patents for market success; any failure to secure or maintain these patents could severely impact the company's valuation. Financially, Stoke recorded a net loss of $6.9 million for the year 2025, with expectations of continuing losses and no anticipated profitability for several years. Moreover, the company must seek additional capital to sustain operations, raising concerns regarding potential dilution of shareholder equity through future equity financings.

STOK has been analyzed by 9 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 22% recommend Buy, 11% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Stoke Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Stoke Therapeutics Inc (STOK) Forecast

Analysts have given STOK a Strong Buy based on their latest research and market trends.

According to 9 analysts, STOK has a Strong Buy consensus rating as of Mar 31, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $39.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $39.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Stoke Therapeutics Inc (STOK)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.